John Beaver is a pioneer in the use of imaging to assess CNS drug target engagement and pharmacodynamics. He is currently VP, Head of Biomarkers, at Biogen, where he leads a team of ~80 scientists utilizing biomarker and bioanalytical measurements in the development of pharmaceuticals to select patients and assess drug safety, target engagement, immunogenicity, pharmacodynamic effects, and disease progression. Dr Beaver has previously held positions at Abbvie, Maccine, and GSK. He received his undergraduate degree from Rutgers University and completed a PhD and postdoctoral research fellowship at the University of Cambridge.